Identification of ALK and ROS1 Biomarkers and Appropriate Treatment in the Management of Non-Small Cell Lung Cancer

This activity is module 1 of a 4-part webinar curriculum.

Program Description

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer in the United States. Treatment with targeted therapies has dramatically shifted the therapeutic landscape, as non-small cell lung cancer is associated with numerous actionable mutations. Among these therapies are agents targeted for anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) biomarkers. This webinar will focus on the role of ALK and ROS1 gene rearrangements in NSCLC, with an emphasis on the clinical data supporting the use of ALK and ROS1 inhibitors in patients with NSCLC. Additionally, the role of the pharmacist in caring for this patient population will be emphasized.

Target audience: Oncology pharmacists, specialty pharmacists, and health-system pharmacists

Type of activity: Application

Release date: January 31, 2022
Expiration date: January 31, 2023
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

⦁ Identify the role of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) gene rearrangement testing in non-small cell lung cancer (NSCLC)

⦁ Analyze the data supporting ALK and ROS1 tyrosine kinase inhibitors in the management of NSCLC

⦁ Demonstrate the role of oncology pharmacists in the care of patients with ALK- or ROS1-positive NSCLC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number 0290-0000-22-038-H01-P. The activity is available for CE credit through January 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Chung-Shien Lee, PharmD, BCPS, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms